Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 8987 results

  1. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued Reference number: GID-TA10144

  2. Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

    Discontinued Reference number: GID-TA10210

  3. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

  4. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued Reference number: GID-TA10353

  5. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued Reference number: GID-TA10480

  6. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

  7. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

  8. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued Reference number: GID-TA10356

  9. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

  10. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued Reference number: GID-TA10070

  11. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued Reference number: GID-TA10208

  12. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued Reference number: GID-TA10168

  13. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

  14. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued Reference number: GID-TA10689

  15. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631